DescriptionMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex chronic clinical condition characterized by a profound, debilitating fatigue, lasting for at least 6 months affecting both physical and cognitive activities. Although there is evidence of autoimmune nature in a subgroup of ME/CFS patients, aetiology of this disease is still unknown. Regarding uncertainty in diagnostic criteria of ME/CFS, discovery of serum biomarkers in ME/CFS is very important.
The aim of this study was to evaluate the levels of anti-human immunoglobulin (Ig) class antibodies and different cytokines in ME/CFS patients and compare to control group.
126 ME/CFS patients and 31 healthy controls cell-free blood plasma samples were analysed for anti-human Ig class antibodies (anti-human IgM, anti-human IgA, anti-human IgG1, anti-human IgG2, anti-human IgG3 and anti-human IgG4) with Luminex 200 Instrument System using commercially available kit (MILLIPLEX® MAP Human Isotyping Magnetic Bead Panel - Isotyping Multiplex Assay) according to the manufacturer’s protocol. Plasma levels of cytokines IL-2, IL-6, IL-17A, IL-21, IL-23, TNF-a and IFN- γ were analysed in 107 patients and 46 controls with Luminex 200 Instrument System using commercially available kit (MILLIPLEX® MAP Human High Sensitivity T Cell Magnetic Bead Panel).
Although results show reduction in levels of anti-human Ig class antibodies and differences in cytokine levels among ME/CFS patients comparing to controls, further studies are needed to confirm their potential as biomarkers in ME/CFS.
|Period||10 Jun 2022 → 13 Jun 2022|
|Event title||13th International Congress on Autoimmunity|
|Location||Athens, GreeceShow on map|
|Degree of Recognition||International|
Selection of biomarkers in ME/CFS for patient stratification and treatment surveillance / optimisation
Project: Fundamental and Applied Research Programme